Table 2. Outcome measures for individual studies of meta-analysis comparing EUS-FNA with and without ROSE.
| Reference | Pathologist | needle Passes(mean, +SD) | Adequacy(N/Total) | diagnosis yield(N/Total) | definite for malignancy(N/Total) | Score or quality evaluation | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| ROSE+ | ROSE- | ROSE+ | ROSE- | ROSE+ | ROSE- | ROSE+ | ROSE- | |||
| Alsohaibani | Y | NR | NR | NR | NR | 14/22 | 14/22 | 12/22 | 13/22 | 5* |
| Iglesias-Garcia | Y | 2.0+0.7 | 3.5+1.0 | 94/95 | 76/87 | 92/95 | 67/87 | 76/95 | 43/87 | 6* |
| Cleveland | N | NR | NR | 198/200 | 24/24 | NR | NR | NR | NR | 4* |
| Cermak | both | NR | NR | NR | NR | 24/167 | 162/214 | NR | NR | 5* |
| Nayar | N | 4.3+2.5 | 4.1+2.3 | 92/97 | 76/82 | 83/97 | 73/82 | 70/97 | 65/82 | 6* |
| Ganc | N | NR | NR | 23/24 | 19/24 | NR | NR | NR | NR | 5* |
| Wani | Y | NR | NR | 109/121 | 104/120 | 114/121 | 108/120 | 102/121 | 92/120 | High quality# |
ROSE, rapid on-site evaluation; NR, not reported.
#Randomized controlled trials (RCTs) were assessed using the Cochrane Collaboration’s tools for assessing quality.
*Non-randomized trials were assessed using the Newcastle–Ottawa Scale (NOS).